Insider Selling: Eli Lilly And Co (LLY) Major Shareholder Sells $22,984,239.20 in Stock

Eli Lilly And Co (NYSE:LLY) major shareholder Lilly Endowment Inc sold 202,540 shares of the stock in a transaction that occurred on Monday, November 12th. The stock was sold at an average price of $113.48, for a total value of $22,984,239.20. Following the completion of the transaction, the insider now directly owns 118,814,164 shares of the company’s stock, valued at $13,483,031,330.72. The sale was disclosed in a filing with the SEC, which is available through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Lilly Endowment Inc also recently made the following trade(s):

  • On Wednesday, October 17th, Lilly Endowment Inc sold 174,696 shares of Eli Lilly And Co stock. The stock was sold at an average price of $113.25, for a total value of $19,784,322.00.
  • On Monday, October 8th, Lilly Endowment Inc sold 14,632 shares of Eli Lilly And Co stock. The stock was sold at an average price of $115.91, for a total value of $1,695,995.12.
  • On Wednesday, October 3rd, Lilly Endowment Inc sold 78,962 shares of Eli Lilly And Co stock. The stock was sold at an average price of $109.01, for a total value of $8,607,647.62.
  • On Thursday, September 27th, Lilly Endowment Inc sold 92,447 shares of Eli Lilly And Co stock. The shares were sold at an average price of $107.00, for a total value of $9,891,829.00.
  • On Tuesday, September 25th, Lilly Endowment Inc sold 55,590 shares of Eli Lilly And Co stock. The shares were sold at an average price of $106.41, for a total value of $5,915,331.90.
  • On Friday, September 7th, Lilly Endowment Inc sold 180,000 shares of Eli Lilly And Co stock. The shares were sold at an average price of $106.76, for a total value of $19,216,800.00.
  • On Thursday, August 30th, Lilly Endowment Inc sold 190,000 shares of Eli Lilly And Co stock. The shares were sold at an average price of $105.42, for a total value of $20,029,800.00.
  • On Monday, August 20th, Lilly Endowment Inc sold 195,000 shares of Eli Lilly And Co stock. The shares were sold at an average price of $105.89, for a total value of $20,648,550.00.
  • On Wednesday, August 15th, Lilly Endowment Inc sold 151,793 shares of Eli Lilly And Co stock. The shares were sold at an average price of $103.23, for a total value of $15,669,591.39.

Shares of NYSE:LLY opened at $112.20 on Friday. Eli Lilly And Co has a one year low of $73.69 and a one year high of $116.61. The firm has a market cap of $119.92 billion, a PE ratio of 26.21, a P/E/G ratio of 1.81 and a beta of 0.29. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.91 and a quick ratio of 1.53.

Eli Lilly And Co (NYSE:LLY) last announced its quarterly earnings data on Tuesday, November 6th. The company reported $1.39 EPS for the quarter, beating analysts’ consensus estimates of $1.35 by $0.04. Eli Lilly And Co had a return on equity of 42.84% and a net margin of 1.85%. The company had revenue of $6.06 billion during the quarter, compared to the consensus estimate of $6.04 billion. During the same quarter in the prior year, the firm earned $1.05 EPS. The company’s quarterly revenue was up 7.1% compared to the same quarter last year. On average, equities research analysts expect that Eli Lilly And Co will post 5.57 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 10th. Stockholders of record on Thursday, November 15th will be given a dividend of $0.5625 per share. The ex-dividend date is Wednesday, November 14th. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.01%. Eli Lilly And Co’s dividend payout ratio (DPR) is presently 52.57%.

A number of equities analysts have issued reports on the company. Cantor Fitzgerald set a $100.00 price target on Eli Lilly And Co and gave the company a “buy” rating in a research note on Tuesday, July 24th. ValuEngine raised Eli Lilly And Co from a “hold” rating to a “buy” rating in a research note on Monday. Societe Generale set a $106.00 price target on Eli Lilly And Co and gave the company a “hold” rating in a research note on Wednesday, November 7th. BMO Capital Markets increased their price target on Eli Lilly And Co from $80.00 to $90.00 and gave the company a “market perform” rating in a research note on Wednesday, July 25th. They noted that the move was a valuation call. Finally, Barclays increased their price target on Eli Lilly And Co from $112.00 to $120.00 and gave the company an “overweight” rating in a research note on Friday, October 12th. Eight research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $111.19.

Several large investors have recently made changes to their positions in LLY. Integrated Wealth Concepts LLC acquired a new stake in shares of Eli Lilly And Co during the 2nd quarter valued at $103,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors acquired a new stake in shares of Eli Lilly And Co during the 2nd quarter valued at $114,000. Legacy Advisors LLC lifted its holdings in shares of Eli Lilly And Co by 118.0% in the second quarter. Legacy Advisors LLC now owns 1,354 shares of the company’s stock valued at $116,000 after purchasing an additional 733 shares in the last quarter. Fort L.P. purchased a new stake in shares of Eli Lilly And Co in the second quarter valued at $121,000. Finally, Welch Group LLC purchased a new stake in shares of Eli Lilly And Co in the third quarter valued at $123,000. Institutional investors own 76.19% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Insider Selling: Eli Lilly And Co (LLY) Major Shareholder Sells $22,984,239.20 in Stock” was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://www.chaffeybreeze.com/2018/11/16/insider-selling-eli-lilly-and-co-lly-major-shareholder-sells-22984239-20-in-stock.html.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Further Reading: Should I follow buy, hold and sell recommendations?

Insider Buying and Selling by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply